Holen Sie sich die Stockscreener-App
4.8066
0.21%
0.0066
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ACHV?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$4.80
Offen:
$4.81
24-Stunden-Volumen:
549.17K
Relative Volume:
0.57
Marktkapitalisierung:
$493.79M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-54.65M
KGV:
-3.7122
EPS:
-1.2948
Netto-Cashflow:
$-49.47M
1W Leistung:
+9.57%
1M Leistung:
+50.31%
6M Leistung:
+4.79%
1J Leistung:
+102.10%
1-Tages-Spanne:
$4.70
$4.85
1-Wochen-Bereich:
$4.20
$4.895
52-Wochen-Spanne:
$2.00
$6.025
Achieve Life Sciences Inc Stock (ACHV) Company Profile
Firmenname
Achieve Life Sciences Inc
Sektor
Branche
Telefon
425-686-1500
Adresse
22722 29TH DR. SE, SEATTLE, BC
Compare ACHV vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACHV
Achieve Life Sciences Inc
|
4.81 | 492.76M | 0 | -54.65M | -49.47M | -1.2948 |
VRTX
Vertex Pharmaceuticals Inc
|
426.40 | 108.54B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
708.50 | 75.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.49 | 50.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.43 | 40.45B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
314.22 | 32.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Achieve Life Sciences Inc Stock (ACHV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-21 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-11-25 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-08-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-14 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-09-27 | Eingeleitet | Raymond James | Strong Buy |
| 2023-05-10 | Bestätigt | Maxim Group | Buy |
| 2021-06-23 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Achieve Life Sciences Inc Aktie (ACHV) Neueste Nachrichten
Achieve Life Sciences (ACHV) to Release Quarterly Earnings on Tuesday - MarketBeat
Achieve Life Sciences to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 12, 2026 - The Manila Times
Achieve Life will post quarterly results before a May 12 webcast - Stock Titan
Achieve Life Sciences : Corporate Presentation April 2026 (ACHV Corporate Deck April) - marketscreener.com
MSN Money - MSN
Achieve Life Sciences (NASDAQ:ACHV) Stock Price Passes Above 200 Day Moving AverageTime to Sell? - MarketBeat
Achieve Life Sciences : Amendment to Annual Report (Form 10-K/A) - marketscreener.com
Board, pay and ownership details at Achieve Life Sciences (NASDAQ: ACHV) - Stock Titan
Goodwin Advises Marshall Wace On Co-Leading Achieve Life Sciences’ $354 Million Private Placement - Mondaq
venBio Global Strategic Fund V Secures Board Seat at Achieve Life Sciences with 9.99% Stake - TradingView
venBio funds take 9.99% Achieve Life stake, add board seat (ACHV) - Stock Titan
Achieve Life Sciences (ACHV) director Royston Aaron reports zero share ownership - Stock Titan
Achieve Life Sciences stock falls after pricing capital raise of $45M via securities offering - MSN
Achieve Life Sciences announces private placement of up to $354M - MSN
Achieve Life Sciences announces proposed public offering; shares down nearly 13% - MSN
Paradigm discloses 9.2% stake in Achieve Life (NASDAQ: ACHV) - Stock Titan
TPG takes 12.6% Achieve Life Sciences (ACHV) stake via $25M structured deal - Stock Titan
TPG-affiliated holders disclose Achieve Life Sciences (NASDAQ: ACHV) shares and warrants position - Stock Titan
Achieve Life Sciences (ACHV) director files Form 3 reporting zero share ownership - Stock Titan
Frazier Life Sciences (ACHV) holds 6.5% stake; warrants disclosed - Stock Titan
Venrock entities disclose 5.2% stake in Achieve Life (ACHV) after April placement - Stock Titan
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Given Average Rating of "Buy" by Brokerages - MarketBeat
Achieve Life Sciences (NASDAQ:ACHV) Stock Rating Upgraded by Canaccord Genuity Group - MarketBeat
Achieve Life Sciences: Up To $354 Million Private Placement Funds Cytisinicline Development And Commercialization - Pulse 2.0
Achieve Life Sciences (ACHV) grants CEO large PRSU, option and RSU awards - Stock Titan
ACHIEVE LIFE SCIENCES (ACHV) CEO files Form 3 reporting zero beneficial ownership - Stock Titan
ACHV Initiates Coverage On Canaccord Genuity -- Rating Set to Bu - GuruFocus
Canaccord Genuity Initiates Coverage on Achieve Life Sciences With Buy Rating, $13 Price Target - marketscreener.com
Achieve Life Sciences flags FDA observations while pushing launch to 2027 for smoking cessation med - MSN
Bothell biotech names new CEO, looks to raise $354 million - The Business Journals
Achieve Life Sciences to Host Meetings During the J.P. Morgan He - GuruFocus
Analysts Offer Insights on Healthcare Companies: Achieve Life Sciences (ACHV), Decibel Cannabis Company (OtherDBCCF) and Eli Lilly & Co (LLY) - The Globe and Mail
Achieve Life Sciences secures $354M financing deal By Investing.com - Investing.com Australia
Achieve Life Sciences names new CEO, adds board members By Investing.com - Investing.com Australia
Achieve Life Sciences Raises Capital, Appoints New CEO - The Globe and Mail
Achieve Life Sciences Secures Up to $354 Million Private Placement to Advance Cytisinicline for Smoking and Vaping Cessation - Minichart
Achieve Life Sciences (ACHV) Secures $354M Through Private Place - GuruFocus
$354M funding and new CEO reshape Achieve Life Sciences (NASDAQ: ACHV) - Stock Titan
ACHV Stock On Track To For Best Day In Over 7 Years — What’s Driving The Rally? - Stocktwits
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Achieve Life Sciences names new CEO, adds board members - Investing.com
Achieve Life Sciences secures $354M financing deal - Investing.com
ACHV Reiterates by HC Wainwright & Co. -- Price Target Maintained at $12 - GuruFocus
Finanzdaten der Achieve Life Sciences Inc-Aktie (ACHV)
Umsatz
Nettogewinn
Free Cashflow
ENV
Achieve Life Sciences Inc-Aktie (ACHV) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Oki Mark K | Chief Financial Officer |
Sep 18 '25 |
Sale |
2.92 |
50,060 |
146,175 |
127,940 |
| Stewart Richard Alistair | Chief Executive Officer |
Sep 18 '25 |
Option Exercise |
0.00 |
297,500 |
0 |
358,376 |
| Stewart Richard Alistair | Chief Executive Officer |
Sep 18 '25 |
Sale |
2.92 |
129,501 |
378,143 |
228,875 |
| Wan Jerry | Principal Accounting Officer |
Sep 04 '25 |
Option Exercise |
0.00 |
34,100 |
0 |
46,764 |
| Wan Jerry | Principal Accounting Officer |
Sep 04 '25 |
Sale |
2.77 |
14,070 |
38,974 |
32,694 |
| KING THOMAS BRAXTON | Director |
Sep 04 '25 |
Option Exercise |
0.00 |
455,000 |
0 |
455,000 |
| KING THOMAS BRAXTON | Director |
Sep 04 '25 |
Sale |
2.77 |
139,858 |
387,407 |
315,142 |
| JACOBS CINDY | President & CMO |
Sep 04 '25 |
Option Exercise |
0.00 |
110,000 |
0 |
143,214 |
| JACOBS CINDY | President & CMO |
Sep 04 '25 |
Sale |
2.77 |
27,629 |
76,532 |
115,585 |
| Xinos Jaime | Chief Commercial Officer |
Sep 04 '25 |
Option Exercise |
0.00 |
69,000 |
0 |
95,286 |
5.78%
0.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):